$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale Creating readiness for first production runs of potential commercial launches, including ...
Standard Parkinson’s disease treatment continues to be old drugs that get nerve cells to make dopamine, a brain chemical whose deficiency drives the central nervous system disorder. Bayer is taking a ...
BERLIN--(BUSINESS WIRE)--Bayer AG announced today that BlueRock Therapeutics (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, successfully administered ...
Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer to further strengthen cardiovascular portfolio and enter dynamic field of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results